We suggested expanding the sample size and conducting patient follow-up to investigate further the relationship between LEAP-2 levels and liver fibrosis, and cirrhosis, and exclude the influence of alcohol factors. This evidence concerns the gene LEAP2 and Hepatic fibrosis.